EGFR and ovarian cancer: Both AG1478 and Erotinib are quinazolines [49], inhibit the EGFR by binding the ATP site thereby preventing autophosphorylation of the receptor [50] and have been linked to reversal of drug resistance [49,51] or modulation of drug resistance in ovarian cancer [50,52].